{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:11:09Z","timestamp":1787839869265,"version":"build-2784847793"},"reference-count":38,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: Vaccines for COVID-19 have had a significant impact on the spread of COVID-19 infection, reducing the incidence and mortality of the infection in several countries. However, hesitancy toward this vaccine is a global health issue for the general population The Vaccine acceptance rate among patients affected with inherited metabolic disorders (IMD), as well as safety profile, has not been described. Methods: We conducted a cross-sectional study, based on a telephone survey, investigating the COVID-19 vaccination rate, the incidence and type of adverse effects (AEs), the reasons for vaccine refusal and the effects on the underlying disease in a cohort of IMD patients followed at a single center and invited directly to vaccination by specialistic team. Results: Seventy-four patients were included in the study, the median age was 23.4 years (min 12.1\u2013max 61.7), 47% (n = 85) were females and 61% (107) were affected from impaired metabolism of phenylalanine. By October 2021, 94% (n = 163) of them had received at least one dose of the vaccine, which was, in 98% of cases, mRNA-based vaccine, given at the referral hospital in 65% of cases. Overall, 72% of patients with IMD reported AE to the vaccine: 60% after the first dose, 81% after the second. The highest rate of adverse events at the first dose was reported in patients with amino acids related disorders other than impaired phenylalanine metabolism (PKU\/HPA) (88%). For the second dose, the PKU\/HPA group reported the highest rate of AEs (89% of cases). There was no effect on the underlying disease or acute decompensation after the vaccine. Eleven patients (6%) were not vaccinated because they considered it dangerous. Conclusion: Among individuals with IMD, the vaccination rate was high, the incidence and severity of AEs were comparable to those in the general population with no effects on the disease. Direct contact with the specialist medical team, has proven to reassure patients and effectively contrast hesitancy.<\/jats:p>","DOI":"10.3390\/ijerph191912227","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T23:12:12Z","timestamp":1664320332000},"page":"12227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 Vaccine in Inherited Metabolic Disorders Patients: A Cross-Sectional Study on Rate of Acceptance, Safety Profile and Effect on Disease"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-8061","authenticated-orcid":false,"given":"Albina","family":"Tummolo","sequence":"first","affiliation":[{"name":"Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-7465","authenticated-orcid":false,"given":"Annamaria","family":"Dicintio","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Paterno","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Carella","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2592-8767","authenticated-orcid":false,"given":"Livio","family":"Melpignano","sequence":"additional","affiliation":[{"name":"Medical Direction, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"De Giovanni","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases, Clinical Genetics and Diabetology, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale, 70126 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization Media Center (2000, May 15). Global Alliance for Vaccines and Immunization. 2011. Fact Sheet No. 169. . Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/79077?show=full."},{"key":"ref_2","first-page":"238","article-title":"Vaccine hypersensitivity\u2014Update and overview","volume":"140","author":"Fritsche","year":"2010","journal-title":"Swiss Med. Wkly."},{"key":"ref_3","unstructured":"World Health Organisation (2022, March 05). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/COVID-19.who.int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"03076","DOI":"10.7189\/jogh.11.03076","article-title":"The largest vaccination campaign in history: A golden opportunity for bundling public health interventions","volume":"11","author":"Tatar","year":"2021","journal-title":"J. Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A randomised, double-blind, and placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bueno, S.M., Abarca, K., Gonz\u00e1lez, P.A., G\u00e1lvez, N.M., Soto, J.A., Duarte, L.F., Schultz, B.M., Pacheco, G.A., Gonz\u00e1lez, L.A., and V\u00e1zquez, Y. (2021). Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. MedRxiv.","DOI":"10.1101\/2021.03.31.21254494"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wu, Q., Dudley, M.Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D., and Yu, H. (2021). Evaluation of the safety profile of COVID-19 vaccines: A rapid review. BMC Med., 19.","DOI":"10.1186\/s12916-021-02059-5"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41591-021-01490-8","article-title":"Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy","volume":"27","author":"Dagan","year":"2021","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lv, M., Luo, X., Shen, Q., Lei, R., Liu, X., Liu, E., Li, Q., and Chen, Y. (2021). Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines, 9.","DOI":"10.1101\/2021.09.11.21262855"},{"key":"ref_11","unstructured":"(2022, August 22). Clinical Guidance on COVID-19 Vaccines for People with Metabolically Unstable Inborn Errors of Metabolism. Available online: http:\/\/www.bccdc.ca\/Health-Info-Site\/Documents\/COVID19_vaccine\/IEM_Clinical_Guidance.pdf."},{"key":"ref_12","unstructured":"National Advisory Committee on Immunization (2021, March 01). Recommendations on the Use of COVID-19 Vaccine(s). Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/recommendations-use-covid-19-vaccines.html."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41591-021-01459-7","article-title":"Understanding COVID-19 vaccine hesitancy","volume":"27","author":"Machingaidze","year":"2021","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: Definition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4161\/hv.24657","article-title":"Vaccine hesitancy: An overview","volume":"9","author":"Laberge","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_16","unstructured":"(2021, May 08). Raccomandazioni ad Interim sui Gruppi Target Della Vaccinazione Anti SARS-CoV-2\/COVID-19 Published on Gazzetta Ufficiale on 24 Marzo 2021. Available online: https:\/\/www.vaccinarsi.org\/scienza-conoscenza\/combattere-le-pandemie\/covid-19-disposizioni-e-normative\/raccomandazioni-ad-interim-sui-gruppi-target-della-vaccinazione-anti-sars-cov-2\/covid-19."},{"key":"ref_17","unstructured":"(2021, May 31). Determina AIFA n. 73 del 31 Maggio 2021 \u201cEstensione Indicazioni Terapeutiche di Specialit\u00e0 Medicinali\u201d, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/1289678\/Det_73-2021_est_COMIRNATY.pdf."},{"key":"ref_18","unstructured":"European Reference Network (2021, March 02). Hereditary Metabolic Disorders and COVID-19 Vaccination. Available online: https:\/\/metab.ern-net.eu\/wp-content\/uploads\/2020\/07\/COVID-19-Vaccine.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Tummolo, A., Paterno, G., Dicintio, A., Stefanizzi, P., Melpignano, L., and Aric\u00f2, M. (2021). COVID-19 and Inherited Metabolic Disorders: One-Year Experience of a Referral Center. Children, 8.","DOI":"10.3390\/children8090781"},{"key":"ref_20","unstructured":"(2022, February 06). COVID-19 Vaccination Program Operational Guidance, Available online: https:\/\/www.cdc.gov\/vaccines\/covid-19\/covid19-vaccination-guidance.html."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: A randomized, placebo-controlled, double-blind phase 1 study","volume":"27","author":"Li","year":"2021","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"C4591001 Clinical Trial Group: Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"key":"ref_25","unstructured":"(2022, March 05). European Centre for Disease Prevention and Control. Available online: https:\/\/vaccinetracker.ecdc.europa.eu\/public\/extensions\/covid-19\/vaccine-tracker.html#uptake-tab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-022-02247-3","article-title":"One year of COVID-19: Infection rates and symptoms in patients with inherited metabolic diseases followed by MetabERN","volume":"17","author":"Paneghetti","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5152\/TurkArchPediatr.2022.21367","article-title":"Unmet needs of children with inherited metabolic disorders in the COVID-19 pandemic","volume":"57","author":"Yekeduz","year":"2022","journal-title":"Turk. Arch. Pediatrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymgme.2020.09.004","article-title":"The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspective","volume":"131","author":"Elmonem","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41436-020-0831-4","article-title":"Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: The experience of a metabolic unit in Italy","volume":"22","author":"Fecarotta","year":"2020","journal-title":"Genet. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e29872","DOI":"10.2196\/29872","article-title":"COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey","volume":"8","author":"Tsai","year":"2022","journal-title":"JMIR Public Health Surveill."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/S2665-9913(21)00416-1","article-title":"Systemic sclerosis and COVID-19 vaccines: A SPIN Cohort study","volume":"4","author":"Gordon","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1756-185X.14279","article-title":"Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study","volume":"25","author":"Haslak","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13052-021-00998-6","article-title":"Breastfeeding and COVID-19 vaccination: Position statement of the Italian scientific societies","volume":"47","author":"Davanzo","year":"2021","journal-title":"Ital. J. Pediatrics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.vaccine.2015.10.073","article-title":"Vaccination coverage of patients with inborn errors of metabolism and the attitudes of their parents towards vaccines","volume":"33","author":"Cerutti","year":"2015","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1542\/peds.2010-3706","article-title":"Evaluation of immunization rates and safety among children with inborn errors of metabolism","volume":"127","author":"Klein","year":"2011","journal-title":"Pediatrics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejpn.2021.10.002","article-title":"Safety and recommendations for vaccinations of children with inborn errors of metabolism","volume":"35","author":"Dragoumi","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1147","DOI":"10.1542\/peds.2010-1628","article-title":"Urea Cycle Disorders Consortium. Vaccines are not associated with metabolic events in children with urea cycle disorders","volume":"127","author":"Morgan","year":"2011","journal-title":"Pediatrics"},{"key":"ref_38","first-page":"14","article-title":"Children with inherited disorders tolerate routine vaccines as well as healthy children","volume":"24","author":"Klein","year":"2011","journal-title":"Pediatrics"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/19\/12227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:40:08Z","timestamp":1760143208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/19\/12227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":38,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijerph191912227"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191912227","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]}}}